162 related articles for article (PubMed ID: 8449603)
21. Deletion of the p16 and p15 genes in human bladder tumors.
Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
[TBL] [Abstract][Full Text] [Related]
22. The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.
Borg A; Zhang QX; Alm P; Olsson H; Sellberg G
Cancer Res; 1992 May; 52(10):2991-4. PubMed ID: 1581913
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.
Logothetis CJ; Xu HJ; Ro JY; Hu SX; Sahin A; Ordonez N; Benedict WF
J Natl Cancer Inst; 1992 Aug; 84(16):1256-61. PubMed ID: 1640485
[TBL] [Abstract][Full Text] [Related]
24. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
25. Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and grade.
Wada T; Louhelainen J; Hemminki K; Adolfsson J; Wijkström H; Norming U; Borgström E; Hansson J; Sandstedt B; Steineck G
Clin Cancer Res; 2000 Feb; 6(2):610-5. PubMed ID: 10690546
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.
Sanchez-Carbayo M; Socci ND; Charytonowicz E; Lu M; Prystowsky M; Childs G; Cordon-Cardo C
Cancer Res; 2002 Dec; 62(23):6973-80. PubMed ID: 12460915
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors associated with loss of heterozygosity at the RB1 locus in retinoblastoma.
Munier FL; Thonney F; Balmer A; Uffer S; Héon E; Van Melle G; Rutz HP; Pescia G; Schorderet DF
Ophthalmic Genet; 1997 Mar; 18(1):7-12. PubMed ID: 9134545
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.
Hurst CD; Tomlinson DC; Williams SV; Platt FM; Knowles MA
Oncogene; 2008 Apr; 27(19):2716-27. PubMed ID: 18037967
[TBL] [Abstract][Full Text] [Related]
29. Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study.
Pietruszewska W; Klatka J; Borzecki A; Rieske P
Folia Histochem Cytobiol; 2008; 46(4):479-85. PubMed ID: 19141402
[TBL] [Abstract][Full Text] [Related]
30. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas.
Ittmann MM; Wieczorek R
Hum Pathol; 1996 Jan; 27(1):28-34. PubMed ID: 8543307
[TBL] [Abstract][Full Text] [Related]
31. High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder.
Natrajan R; Louhelainen J; Williams S; Laye J; Knowles MA
Cancer Res; 2003 Nov; 63(22):7657-62. PubMed ID: 14633686
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.
Kim TM; Benedict WF; Xu HJ; Hu SX; Gosewehr J; Velicescu M; Yin E; Zheng J; D'Ablaing G; Dubeau L
Cancer Res; 1994 Feb; 54(3):605-9. PubMed ID: 8306317
[TBL] [Abstract][Full Text] [Related]
33. Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder.
Diaz-Cano SJ; Blanes A; Rubio J; Matilla A; Wolfe HJ
Lab Invest; 2000 Mar; 80(3):279-89. PubMed ID: 10744064
[TBL] [Abstract][Full Text] [Related]
34. Allelotype of human bladder cancer.
Knowles MA; Elder PA; Williamson M; Cairns JP; Shaw ME; Law MG
Cancer Res; 1994 Jan; 54(2):531-8. PubMed ID: 8275491
[TBL] [Abstract][Full Text] [Related]
35. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
36. Rb-loss is associated with high malignancy in chondrosarcoma.
Röpke M; Boltze C; Meyer B; Neumann HW; Roessner A; Schneider-Stock R
Oncol Rep; 2006 Jan; 15(1):89-95. PubMed ID: 16328039
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study.
Gras E; Pons C; Machin P; Matias-Guiu X; Prat J
Int J Gynecol Pathol; 2001 Oct; 20(4):335-40. PubMed ID: 11603216
[TBL] [Abstract][Full Text] [Related]
38. p53 and RB expression predict progression in T1 bladder cancer.
Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
[TBL] [Abstract][Full Text] [Related]
39. Abnormalities and the implication of retinoblastoma locus and its protein product in head and neck cancers.
Yokoyama J; Shiga K; Sasano H; Suzuki M; Takasaka T
Anticancer Res; 1996; 16(2):641-4. PubMed ID: 8687109
[TBL] [Abstract][Full Text] [Related]
40. Mutation spectrum of the retinoblastoma gene in osteosarcomas.
Wadayama B; Toguchida J; Shimizu T; Ishizaki K; Sasaki MS; Kotoura Y; Yamamuro T
Cancer Res; 1994 Jun; 54(11):3042-8. PubMed ID: 8187094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
